Improving Prognosis for Kidney Disorders

ISBN-13: 9789048161645 / Angielski / Miękka / 2010 / 134 str.

M. M. Avram

Opis

More than half a million people worldwide are now sustained by renal replacement therapy, mainly hemodialysis at a cost exceeding USD 30 billion per year. Each case of ESRD that is delayed or prevented saves funds that may be applied to other aspects of health care. Edited by an internationally renowned nephrologist, Prognosis for Kidney Disorders provides a timely summary of exciting work in progress directed toward renoprotection and of ultimate interdiction of ESRD.
Suitable for researchers and clinicians, Dr. Morrell Michael Avram has collected and commented on promising initiatives likely to enter everyday practice in the immediate future. Suitable for renal trainees, experienced kidney doctors, nurses, nutritionists and cardiologists.

Spis treści

List of Principal Authors. Dedication. Introduction; M.M. Avram. 1. How to Achieve Maximal Protection in Non-Diabetic Chronic Renal Disease; M.W. Taal, B.M. Brenner. 2. Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa; A.R. Nissenson, E.M. Tong. 3. Cardiovascular Disease in Patients with Chronic Kidney Disease: The Causes and Effects; A. Levin, et al. 4. Metabolic Pathogenesis of Cardio-Renal Disease; W.F. Keane. 5. Oxidative Stress and Inflammation in Hemodialysis Patients; N.W. Levin, et al. 6. Prognostic Value of Enrollment Parathyroid Hormone in Hemodialysis and Peritoneal Dialysis Patients for Survival. A 14 Years Follow-up; 7. Prealbumin as an Important Predictor for Survival and Nutritional Status in Hemodialysis and Peritoneal Dialysis Patients; N. Mittman, et al. 8. How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria; D. de Zeeuw, et al. 9. Hypoalbuminemia in the Patient with Renal Disease; G.A. Kaysen. 10. Kidney Disease and Mechanisms that Cause Loss of Muscle Mass; W.E. Mitch, S.R. Price. 11. Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy; 12. Effects of Erythropoietin (EPO) and Aminoguanidine (AG) on Deformability (df) in Diabetic Azotemic and Uremic Patients; E.A. Friedman, et al. 13. Characterization of the PKD1 Gene Product, Polycystin-1; 14. Nutrition and Blood Pressure; J.D. Kopple. 15. How to Minimize Bone Disease in Renal Failure; K.J. Martin, E.A. González. Index.